RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,252 from $1,282 and keeps an Outperform rating on the shares. The firm notes the District Court of West Virginia has denied the company’s motion for a preliminary injunction vs. Amgen (AMGN), and the expectations are that the launch of biosimilar aflibercept may be imminent. While the Eylea/EyleaHD franchise was not the core of RBC’s bullish thesis, and the firm had already anticipated and modeled a biosimilar launch by early-2026, it believes this news has caused some consternation. RBC continues to believe growth from the rest of the portfolio will more than offset ophtho erosion and remains a buyer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Walmart upgraded, Starbucks downgraded: Wall Street’s top analyst calls
- Regeneron weakness to Amgen injuction ruling an ‘overreaction’, says Truist
- Leerink cuts Regeneron to Market Perform on Eylea franchise outlook uncertainty
- Regeneron downgraded to Market Perform from Outperform at Leerink
- Judge’s denial of Regeneron motion against Amgen a ‘speedbump’, says BMO Capital